Nasdaq · CIK 0001650648
FDMT 4D Molecular Therapeutics, Inc.
Insider trading from SEC Form 4. Last filing 5 d ago. Close $13.33 on Oct 9, 2026, +85% from the 52-week low and -20% from the high.
Last 90 days
Net insider value
-$1.6M
more sold than bought
Buys
0
$0 by 0 insiders
Sells
4
$1.6M by 2 insiders
Insiders on file
13
with a Form 4 at this company
Price and insider trades, last year
FDMTOct 9, 2026 · close 13.33
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at 4D Molecular Therapeutics, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 17Weak | David Kirn See Remarks sell | $754k 58,333 shares | -8% | - | |
| 0Weak | Scott Bizily Chief Legal Officer sell | $22k 1,635 shares | -16% | - | |
| 25Weak | David Kirn See Remarks sell | $811k 58,333 shares | -7% | - | |
| 0Weak | Scott Bizily Chief Legal Officer sell | $8,176 584 shares | -6% | - |
Transactions
The last 28 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Oct 5, 2026 | David Kirn See Remarks | SOpen-market sale Common Stock10b5-1 | -58,061 | $12.92 | $750k | 709,425 | 5 d ago |
| Oct 5, 2026 | David Kirn See Remarks | SOpen-market sale Common Stock10b5-1 | -272 | $13.61 | $3,702 | 709,153 | 5 d ago |
| Sep 16, 2026 | Scott Bizily Chief Legal Officer | MOption exercise Common Stock10b5-1 | +1,635 | $4.14 | $6,769 | 10,252 | 20 d ago |
| Sep 16, 2026 | Scott Bizily Chief Legal Officer | SOpen-market sale Common Stock10b5-1 | -1,635 | $13.65 | $22k | 8,617 | 20 d ago |
| Sep 16, 2026 | Scott Bizily Chief Legal Officer | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -1,635 | $0.00 | $0 | 58,066 | 20 d ago |
| Sep 14, 2026 | David Kirn See Remarks | SOpen-market sale Common Stock10b5-1 | -58,333 | $13.90 | $811k | 767,486 | 26 d ago |
| Sep 1, 2026 | Scott Bizily Chief Legal Officer | MOption exercise Common Stock10b5-1 | +584 | $6.49 | $3,790 | 9,201 | 39 d ago |
| Sep 1, 2026 | Scott Bizily Chief Legal Officer | SOpen-market sale Common Stock10b5-1 | -584 | $14.00 | $8,176 | 8,617 | 39 d ago |
| Sep 1, 2026 | Scott Bizily Chief Legal Officer | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -584 | $0.00 | $0 | 2,959 | 39 d ago |
| Jun 17, 2025 | Jacob Chacko director | AGrant or award Stock Option (Right to Buy)derivative | +22,500 | $0.00 | $0 | 22,500 | Jun 20, 2025 |
| Jun 17, 2025 | Susannah Gray director | AGrant or award Stock Option (Right to Buy)derivative | +22,500 | $0.00 | $0 | 22,500 | Jun 20, 2025 |
| Jun 17, 2025 | Shawn Tomasello director | AGrant or award Stock Option (Right to Buy)derivative | +22,500 | $0.00 | $0 | 22,500 | Jun 20, 2025 |
| Jun 17, 2025 | Charles Theuer director | AGrant or award Stock Option (Right to Buy)derivative | +22,500 | $0.00 | $0 | 22,500 | Jun 20, 2025 |
| Jun 17, 2025 | Nancy Miller-Rich director | AGrant or award Stock Option (Right to Buy)derivative | +22,500 | $0.00 | $0 | 22,500 | Jun 20, 2025 |
| Jun 17, 2025 | John F Milligan director | AGrant or award Stock Option (Right to Buy)derivative | +33,750 | $0.00 | $0 | 33,750 | Jun 20, 2025 |
| Mar 6, 2025 | Fariborz Kamal President & COO | AGrant or award Stock Option (Right to Buy)derivative | +178,400 | $0.00 | $0 | 178,400 | Mar 10, 2025 |
| Mar 6, 2025 | Uneek Mehra See Remarks | AGrant or award Stock Option (Right to Buy)derivative | +130,000 | $0.00 | $0 | 130,000 | Mar 10, 2025 |
| Mar 6, 2025 | Robert Young Kim Chief Medical Officer | AGrant or award Stock Option (Right to Buy)derivative | +92,300 | $0.00 | $0 | 92,300 | Mar 10, 2025 |
| Mar 6, 2025 | David Kirn Chief Executive Officer | AGrant or award Stock Option (Right to Buy)derivative | +267,500 | $0.00 | $0 | 267,500 | Mar 10, 2025 |
| Mar 6, 2025 | Scott Bizily Chief Legal Officer | AGrant or award Stock Option (Right to Buy)derivative | +78,500 | $0.00 | $0 | 78,500 | Mar 10, 2025 |
| Dec 9, 2024 | Ra Capital Management, L.p. owner | JOther Common Stockindirect: See footnotes | -535,000 | $0.00 | $0 | 4,563,211 | Dec 10, 2024 |
| Dec 9, 2024 | Ra Capital Management, L.p. owner | JOther Pre-Funded Warrants (Right to Buy)derivativeindirect: See footnotes | +535,000 | - | - | 3,610,000 | Dec 10, 2024 |
| Nov 8, 2024 | Bvf Partners L P/il other | JOther Common Stock, $0.0001 par value | -3,062,000 | - | - | 830,237 | Nov 13, 2024 |
| Nov 8, 2024 | Bvf Partners L P/il other | JOther Common Stock, $0.0001 par value | -2,378,000 | - | - | 662,970 | Nov 13, 2024 |
| Nov 8, 2024 | Bvf Partners L P/il other | JOther Common Stock, $0.0001 par value | -240,000 | - | - | 87,911 | Nov 13, 2024 |
| Nov 8, 2024 | Bvf Partners L P/il other | JOther Pre-Funded Warrantderivative | +3,062,000 | - | - | 3,062,000 | Nov 13, 2024 |
| Nov 8, 2024 | Bvf Partners L P/il other | JOther Pre-Funded Warrantderivative | +2,378,000 | - | - | 2,378,000 | Nov 13, 2024 |
| Nov 8, 2024 | Bvf Partners L P/il other | JOther Pre-Funded Warrantderivative | +240,000 | - | - | 240,000 | Nov 13, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Bvf Partners L P/ilother, owner, director
- Scott BizilyChief Legal Officer
- Jacob Chackoceo, president, officer, director
- Susannah Graydirector
- Fariborz KamalPresident & COO
- Robert Young KimChief Medical Officer
- David KirnSee Remarks
- John F Milligandirector
- Uneek MehraSee Remarks
- Nancy Miller-Richdirector
- Ra Capital Management, L.p.owner, director
- Charles Theuerdirector
- Shawn Tomasellodirector
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.